TapewireFind a company

person · Reporting owner

Fridriksdottir Hafrun

Disclosed activity across 1 company

Tapewire entity
127160
SEC CIK
0001561458

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063Executive VP, Global R&DMay 17, 2022May 19, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date May 17, 2022 · Filed May 19, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect1,386.514 Reported balance After 2022-05-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2022-05-17 · Sale · Disposed 130,000 · Balance 1,386.514

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 14, 2020 Filed Feb 18, 2020 12:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 17,850 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,532.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 14, 2020 Filed Feb 18, 2020 12:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,353 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,682.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 11, 2020 Filed Feb 13, 2020 12:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 17,850 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-009049 · doc4.xml · derivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,850

Underlying: Ordinary Shares · 17,850 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020.

F2 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 14, 2020.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 10, 2020 Filed Feb 11, 2020 11:57 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 5,544 $12.27 $68,024.88
Disclosure

SEC source: 0001209191-20-008164 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,329.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

Read SEC document
February 09, 2020 Filed Feb 11, 2020 11:57 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 16,120 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-008164 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,241

Underlying: Ordinary Shares · 16,120 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.

F5 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2020 Filed Feb 11, 2020 11:57 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 16,120 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-008164 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,873.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
December 31, 2019 Filed Jan 2, 2020 11:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 4,640 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-000005 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 4,640 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019.

F6 · derivative.expiration_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
December 31, 2019 Filed Jan 2, 2020 11:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 2,459 $9.92 $24,396.23
Disclosure

SEC source: 0001209191-20-000005 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,753.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.92 to $9.9238, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
December 31, 2019 Filed Jan 2, 2020 11:08 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 4,640 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-000005 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,212.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
December 02, 2019 Filed Dec 3, 2019 11:32 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 4,310 $10.49 $45,214.49
Disclosure

SEC source: 0001209191-19-058620 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,572.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.490 to $10.495, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
November 30, 2019 Filed Dec 3, 2019 11:32 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 8,133 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-058620 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 8,133 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019.

F6 · derivative.expiration_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
November 30, 2019 Filed Dec 3, 2019 11:32 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 8,133 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-058620 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,882.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 18, 2019 Filed Mar 19, 2019 12:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 93 $16.63 $1,546.13
Disclosure

SEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,749.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 18, 2019 Filed Mar 19, 2019 12:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 263 $16.63 $4,372.40
Disclosure

SEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,842.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.5800 to $16.6800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2019 Filed Mar 19, 2019 12:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 265 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-020157 · doc4.xml · derivative · entry 6

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 266

Underlying: Ordinary Shares · 265 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.

F7 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2019 Filed Mar 19, 2019 12:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 747 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-020157 · doc4.xml · derivative · entry 5

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 748

Underlying: Ordinary Shares · 747 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.

F6 · derivative.expiration_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2019 Filed Mar 19, 2019 12:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 265 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,105.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 17, 2019 Filed Mar 19, 2019 12:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 747 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-020157 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,840.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2019 Filed Mar 5, 2019 12:16 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,165 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-016085 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,165 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019.

F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2019 Filed Mar 5, 2019 12:16 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 409 $16.88 $6,905.27
Disclosure

SEC source: 0001209191-19-016085 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,093.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.755 to $17.130, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2019 Filed Mar 5, 2019 12:16 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,165 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-016085 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,502.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2019 Filed Mar 6, 2019 12:14 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 56,716 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-017230 · doc4.xml · derivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,716

Underlying: Ordinary Shares · 56,716 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023.

F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 14, 2019 Filed Feb 19, 2019 12:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,353 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-010837 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,708

Underlying: Ordinary Shares · 5,353 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.

F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 14, 2019 Filed Feb 19, 2019 12:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 1,841 $17.67 $32,528.63
Disclosure

SEC source: 0001209191-19-010837 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,337.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.66 to $17.675, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 14, 2019 Filed Feb 19, 2019 12:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,353 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-010837 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,178.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
January 02, 2019 Filed Jan 3, 2019 12:24 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 1,643 $15.70 $25,799.21
Disclosure

SEC source: 0001209191-19-000609 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,825.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.7 to $15.705, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
December 31, 2018 Filed Jan 3, 2019 12:24 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 4,640 $0.00 $0.00
Disclosure

SEC source: 0001209191-19-000609 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,640

Underlying: Ordinary Shares · 4,640 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019.

F6 · derivative.expiration_date: Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
December 31, 2018 Filed Jan 3, 2019 12:24 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 4,640 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-19-000609 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,468.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
November 30, 2018 Filed Dec 4, 2018 13:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 2,711 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-060707 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,133

Underlying: Ordinary Shares · 2,711 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019.

F5 · derivative.expiration_date: Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
November 30, 2018 Filed Dec 4, 2018 13:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 933 $21.76 $20,304.04
Disclosure

SEC source: 0001209191-18-060707 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,828.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.7600 to $21.7638, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
November 30, 2018 Filed Dec 4, 2018 13:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 2,711 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-060707 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,761.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 19, 2018 Filed Mar 20, 2018 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 91 $17.88 $1,626.90
Disclosure

SEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,050.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 19, 2018 Filed Mar 20, 2018 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 257 $17.88 $4,594.65
Disclosure

SEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,141.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.83 to $17.925, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2018 Filed Mar 20, 2018 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 265 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-020859 · doc4.xml · derivative · entry 6

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 531

Underlying: Ordinary Shares · 265 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.

F6 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2018 Filed Mar 20, 2018 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 747 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-020859 · doc4.xml · derivative · entry 5

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,495

Underlying: Ordinary Shares · 747 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F5 · derivative.exercise_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.

F5 · derivative.expiration_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2018 Filed Mar 20, 2018 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 265 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,398.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 17, 2018 Filed Mar 20, 2018 20:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 747 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-020859 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,133.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2018 Filed Mar 6, 2018 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 3,432 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-017207 · doc4.xml · derivative · entry 6

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,432 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on May 8, 2014 and vest on March 5, 2018.

F4 · derivative.expiration_date: Restricted share units were granted on May 8, 2014 and vest on March 5, 2018.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2018 Filed Mar 6, 2018 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Tax withholdingOrdinary Shares 1,155 $19.38 $22,383.90
Disclosure

SEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,386.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2018 Filed Mar 6, 2018 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Tax withholdingOrdinary Shares 400 $19.38 $7,752.00
Disclosure

SEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,541.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2018 Filed Mar 6, 2018 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 3,432 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,941.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2018 Filed Mar 6, 2018 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 1,165 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-017207 · doc4.xml · derivative · entry 5

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,165

Underlying: Ordinary Shares · 1,165 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F3 · derivative.exercise_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019.

F3 · derivative.expiration_date: Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2018 Filed Mar 6, 2018 21:12 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 1,165 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-017207 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,509.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2018 Filed Feb 12, 2018 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 48,361 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-009186 · doc4.xml · derivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,361

Underlying: Ordinary Shares · 48,361 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.

F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2018 Filed Feb 12, 2018 21:21 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantStock Options (right to buy) · Derivative 123,288 $0.00 Strike: $18.61 $0.00
Disclosure

SEC source: 0001209191-18-009186 · doc4.xml · derivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,288

Underlying: Ordinary Shares · 123,288 shares

Expires 2028-02-08

F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 41,096 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022.

F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.